雷利度胺联合地塞米松抗T淋巴瘤细胞作用的研究(4)
[12] Semeraro M，Vacchelli E，Eggermont A，et al. Trial Watch：Lenalidomide-based immunochemotherapy [J]. Oncoimmunology，2013，2(11)：1091-1096.
[13] Viel S，Charrier E，Marais A，et al. Monitoring NK cell activity in patients with hematological malignancies [J]. Oncoimmunology，2013，2(9)：e26011.
[14] Teo SK. Properties of thalidomide and its analogues：implications for anticancer therapy [J]. AAPS J，2005，7(1)：E14-19.
[15] Gupta D，Treon SP，Shima Y，et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion： therapeutic applications [J]. Leukemia，2001，15(12)：1950-1961.
[16] Verhelle D，Corral LG，Wong K，et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells [J]. Cancer Res，2007，67(2)：746-755.
[17] Kotla V，Goel S，Nischal S，et al. Mechanism of action of lenalidomide in hematological malignancies [J]. J Hematol Oncol，2008，2(1)：1-10.
[18] Cavo M，Tacchetti P，Patriarca F，et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before，and consolidation therapy after，double autologous stem-cell transplantation in newly diagnosed multiple myeloma：a randomised phase 3 study [J]. Lancet，2010，376(9758)：2075-2085.
(收稿日期：2016-04-24 本文编辑：程 铭) (李红玲 陈彤 李明玉 张旭霞 齐发梅 王芳)
[13] Viel S，Charrier E，Marais A，et al. Monitoring NK cell activity in patients with hematological malignancies [J]. Oncoimmunology，2013，2(9)：e26011.
[14] Teo SK. Properties of thalidomide and its analogues：implications for anticancer therapy [J]. AAPS J，2005，7(1)：E14-19.
[15] Gupta D，Treon SP，Shima Y，et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion： therapeutic applications [J]. Leukemia，2001，15(12)：1950-1961.
[16] Verhelle D，Corral LG，Wong K，et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells [J]. Cancer Res，2007，67(2)：746-755.
[17] Kotla V，Goel S，Nischal S，et al. Mechanism of action of lenalidomide in hematological malignancies [J]. J Hematol Oncol，2008，2(1)：1-10.
[18] Cavo M，Tacchetti P，Patriarca F，et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before，and consolidation therapy after，double autologous stem-cell transplantation in newly diagnosed multiple myeloma：a randomised phase 3 study [J]. Lancet，2010，376(9758)：2075-2085.
(收稿日期：2016-04-24 本文编辑：程 铭) (李红玲 陈彤 李明玉 张旭霞 齐发梅 王芳)